XML 10 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 6,808 $ 22,544
Available-for-sale investments 77,688 75,622
Other receivables 2,476 2,436
Prepaid expenses 9,944 2,390
Total current assets 96,916 102,992
Restricted cash 3,214 3,484
Property and equipment, net 5,353 5,531
Operating lease, right-of-use assets 5,999 6,727
Financing lease, right-of-use assets 1,639 1,788
Other assets 130 131
Total assets 113,251 120,653
Current liabilities:    
Accounts payable 4,893 3,529
Accrued expenses 9,950 11,559
Current portion of operating lease liability 629 831
Current portion of financing lease liability 507 497
Total current liabilities 15,979 16,416
Long-term operating lease liability, net of current portion 11,693 12,339
Long-term financing lease liability, net of current portion 1,297 1,428
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of March 31, 2024 (unaudited) and December 31, 2023; no shares issued or outstanding as of March 31, 2024 (unaudited) and December 31, 2023
Common stock, $0.001 par value per share; 170,000,000 authorized shares as of March 31, 2024 (unaudited) and December 31, 2023; issued and outstanding shares - 68,354,033 as of March 31, 2024 (unaudited) and 63,286,404 as of December 31, 2023 68 63
Additional paid-in capital 568,070 558,692
Accumulated other comprehensive loss (158) (74)
Accumulated deficit (483,514) (468,023)
Total aTyr Pharma stockholders’ equity 84,466 90,658
Noncontrolling interest in Pangu BioPharma Limited (184) (188)
Total stockholders' equity 84,282 90,470
Total liabilities and stockholders’ equity $ 113,251 $ 120,653